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Abstract
Noncompliance with study medications is an important issue in the design of endpoint clinical trials.
Including noncompliant patient data in an intention-to-treat analysis could seriously decrease study
power. Standard methods for calculating sample size account for noncompliance, but all assume
that noncompliance is noninformative, i.e., that the risk of discontinuation is independent of the risk
of experiencing a study endpoint. Using data from several published clinical trials (OPTIMAAL, LIFE,
RENAAL, SOLVD-Prevention and SOLVD-Treatment), we demonstrate that this assumption is
often untrue, and we discuss the effect of informative noncompliance on power and sample size.
Introduction
Endpoint trials follow patients over a pre-defined period
of time, and the treatments are compared with respect to
the incidence of some clinical endpoint. These trials typi-
cally require a great deal of resources. For example, the
ISIS-IV trial [1] enrolled 58,050 patients with acute myo-
cardial infarction, and the recently-completed ALLHAT
trial [2] enrolled 33,357 patients with hypertension. For
this reason, appropriate calculations of sample size and
power are particularly important. If the sample size is too
large, a great deal of resources may be wasted, but if it is
too small then the entire effort may be in vain.
One issue in these trials is noncompliance with study
drugs, or failure to follow the assigned treatment regimens
(e.g., skipping doses and "drug holidays"). In this paper,
we use the term noncompliance to refer solely to perma-
nent discontinuation of study drug for any reason. We use
the terms noncompliance and discontinuation inter-
changeably. We also assume that noncompliant patients,
like compliant patients, continue in study follow-up for
ascertainment of study endpoints. Noncompliance rates
can be high in a lengthy trial. In the MRC trials [3,4] the
rates exceeded 40%. While noncompliance cannot be
avoided altogether, it can be minimized through diligent
monitoring, and attention. In some respects, therefore,
the compliance rate serves as an indicator for trial quality.
There can be many reasons for noncompliance, such as
side effects in an actively treated group, lack of efficacy in
a placebo group, or development of a new condition that
makes continuation of the study treatment difficult.
Regardless of the reasons, one concern is that study out-
comes in noncompliant patients may not adequately
reflect the effects of their randomized study therapies. For
example, noncompliant patients in a placebo group
might begin taking an effective therapy and experience
clinical benefit, and a noncompliant patient in an experi-
mental group might lose that treatment's benefit once the
treatment is discontinued. In other circumstances, non-
compliance might have little or no impact. For example, a
treatment might have such a long-lasting effect that dis-
continuing it would have no discernable impact during
the remainder of follow-up. It is also possible that
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noncompliance may increase study power, for example, if
a treatment is actually inferior to the control. For most
clinical trials, however, it seems considerably more likely
that inclusion of noncompliant patients in the analysis
will result in a decrease in the apparent effect of the treat-
ment, and therefore will reduce statistical power.
Due to the potential reduction in power, a careful assess-
ment of the expected rates of noncompliance is an impor-
tant component of sample size calculation. We recently
reviewed sample size methods for survival trials [5],
including the following standard methods in common
use: Halperin et al [6]; Wu, Fisher, and DeMets [7]; Freed-
man [8]; Lachin and Foulkes [9], and two methods by
Lakatos [10,11]. The impact of noncompliance on sample
size depends strongly on the assumptions made regarding
event rates subsequent to discontinuation. The most com-
mon assumption is that patients switch to the opposite
treatment, and that event rates in the two groups reverse.
It is usually further assumed that the reversal is immedi-
ate, although some methods allow for the possibility of a
delay or lag in the change in endpoint risk.
One assumption made by all the methods referenced
above is that discontinuation is noninformative, i.e., that
the risk of discontinuation is independent of the risk of an
endpoint. If at some point in a trial, 10% of the patients
in a treatment group have discontinued from study drug,
this assumption suggests that these patients will contrib-
ute roughly 10% of future endpoints. In our experience,
however, this assumption is seldom true – discontinued
patients typically contribute a disproportionate share of
future endpoints. Thus, we define "informative noncom-
pliance" as the situation in which knowledge of whether
or not a patient has discontinued from study medication
provides information on how likely the patient is to expe-
rience a study endpoint in the future. In other words, the
risk of noncompliance is dependent on the risk of an
endpoint.
There are statistical methods for the analysis of clinical tri-
als in the presence of informative noncompliance, includ-
ing structural nested accelerated failure time models [12],
the marginal structural proportional hazards approach
[13], and the complier proportional hazards effect of
treatment method [14]. Despite these methods, the stand-
ard approach in pharmaceutical trials is to include in an
ITT analysis all patients, without regard to compli-
ance[15]. The main disadvantage of this approach is that
the true treatment effect may be underestimated and,
thus, the power may be reduced.
The purpose of this paper is to illustrate the concept of
informative noncompliance through analyses of several
recent clinical trials and through hypothetical examples,
and to discuss the potential impact of this phenomenon
on sample size and power.
Measuring the degree of informative 
noncompliance
To illustrate the concept of informative noncompliance
and to highlight the difficulty in measuring it, we start
with a simple, hypothetical mortality trial. Since our pur-
pose is to investigate informative noncompliance, not the
effect of the treatment, we assume that the treatments are
identical and we present only pooled-group results. Sup-
pose a clinical trial has simultaneously enrolled 11,250
patients to be followed for three years. Further, suppose
that among compliant patients, the risk of death is high
immediately after randomization (10% over the first
year), but low thereafter (1.25% during the 2nd year and
1% during the 3rd year). With respect to discontinuation,
we assume that approximately 1 of every 9 patients is non-
compliant at the start of the trial, and at the end of each of
years 1 and 2, approximately 1 in 9 of the surviving com-
pliant patients becomes noncompliant. We model
informative noncompliance through the assumption that
noncompliant patients have exactly twice the death rate of
compliant patients: 20% during the first year, 2.5% dur-
ing the 2nd year and 2% during the 3rd year.
Table 1 presents the results of this hypothetical trial. Dur-
ing the first year, 1,000 compliant patients and 250 non-
compliant patients died. Between the end of the first year
and the start of the 2nd year, 1,000 of the 9,000 surviving
compliant patients became noncompliant, resulting in
8000 compliant patients and 1250-250+1000 = 2,000
noncompliant patients entering the 2nd year. During the
2nd year, 100 compliant patients and 50 noncompliant
patients died. Between the end of the 2nd year and the start
of the 3rd year, 878 of the surviving compliant patients
became noncompliant, resulting in 7,022 compliant
patients and 2,000-50+878 = 2,828 noncompliant
patients entering the 3rd year.
One simple approach to evaluate the degree of informa-
tive noncompliance would be to calculate crude rates,
based on compliance at the time of death or at the end of
the trial. Using this approach, 1,170 patients were compli-
ant at the time of death and 6,952 surviving patients were
compliant at the end of the trial (the 7,022 who were
compliant at the start of the 3rd year, minus the 70 who
died), resulting in a crude rate of 14.4%. Similarly, 357
patients were noncompliant at the time of death and
2,771 surviving patients were noncompliant at the end of
the trial (the 2,828 who were noncompliant at the start of
the 3rd year, minus the 57 who died), resulting in a crude
rate of 11.4%. Therefore, despite the fact that discontinu-
ation was actually associated with twice the endpoint rate
at any time during the trial, the crude rates would suggestCurrent Controlled Trials in Cardiovascular Medicine 2004, 5:5 http://cvm.controlled-trials.com/content/5/1/5
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that noncompliance was associated with relatively low
risk. Clearly, the crude rates provide an inappropriate
measure of the degree of informative noncompliance.
A second potential approach is to pick a point early in the
trial, determine who is compliant and noncompliant at
that time, and compare patients' crude endpoint rates.
While this approach is reasonable, it has important draw-
backs. 1) It is not clear what point in the trial to choose.
Very early in the trial, the number of noncompliant
patients might be too small to use as a reliable estimate,
and later in the trial the number of future endpoints might
be small. 2) It ignores important information prior to the
chosen point in the trial. 3) Patients who are compliant at
the chosen point in the trial may become noncompliant
prior to having an endpoint.
Using this approach, one could calculate the mortality
rates in the hypothetical example among patients who
were compliant and noncompliant at the start of, say, the
2nd  year. Among the 8,000 compliant patients, the
number of deaths would be 100 during the 2nd year and
approximately 88 during the 3rd year (including the 70
deaths among the patients who remained compliant, plus
an expected 18 deaths among the 878 patients who
became noncompliant at the start of the 3rd year), result-
ing in a crude rate of 2.35%. Among the 2,000 noncom-
pliant patients, the total number of deaths would be
approximately 89 (50 during the 2nd year plus approxi-
mately 39 during the 3 rd year), leading to a crude rate
4.45%. While this method has correctly demonstrated
that noncompliant patients have a higher mortality risk
than compliant patients, it has underestimated the magni-
tude of the difference.
In this paper, we define a time-varying covariate, indicat-
ing whether or not the patient had discontinued by time
t. For example, if a patient discontinues study medication
on day 100, the covariate takes the value 0 for t < 100, and
the value 1 for t ≥ 100. We calculate the hazard ratio asso-
ciated with this covariate in a Cox regression model with
time-to-event as the dependent variable. The assumption
of noninformative noncompliance corresponds to the
hazard ratio associated with this covariate being equal to
1. Note that in the hypothetical example above, if we
assume that all deaths occur at the mid-point of the year,
the Cox regression model appropriately calculates a haz-
ard ratio of 2.00 associated with noncompliance.
When evaluating the association between discontinuation
and endpoint risk, we need to be aware of a potential bias,
which is described through the following example. Sup-
pose the endpoint of interest is death. A patient is taking
study drug when he suffers a stroke, is admitted to hospi-
tal, and is kept alive on life-support for four days before
dying. Since the patient was not taking study drug during
that 4-day period, it might appear that the patient was
noncompliant at the time of death. This would be an
incorrect interpretation, since the patient was compliant
when suffering the event that led to death. Therefore,
when evaluating the impact of compliance on endpoint
risk, we use a 7-day rule, namely that the patient is consid-
ered to be compliant while taking study drug and for 7
days after permanent discontinuation of study drug. Since
the choice of 7 days is somewhat arbitrary, it might be
appropriate to investigate the sensitivity of the results to
this choice.
The Cox model calculates a hazard ratio associated with
noncompliance under the assumption that this hazard
ratio is constant over time. In order to explore visually
whether or not this assumption is true, we create extended
Kaplan-Meier curves that compare endpoint rates for
cohorts defined by time-varying covariates [16]. These
curves are somewhat difficult to interpret but are consist-
ent with the Cox regression method.
Table 1: Hypothetical Illustration of Informative Noncompliance
Start of 
Study Year
Compliant Patients Noncompliant Patients
Number of 
Patients
Endpoint 
Rate
Number of 
Endpoints
New Noncompliant 
Patients
Number of 
Patients
Endpoint 
Rate
Number of 
Endpoints
1 10,000 0.1000 1,000 1,250 0.2000 250
1000
2 8,000 0.0125 100 2,000 0.0250 50
878
3 7,022 0.0100 70 2,828 0.0200 57
Total 1,170 357Current Controlled Trials in Cardiovascular Medicine 2004, 5:5 http://cvm.controlled-trials.com/content/5/1/5
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Examples of informative noncompliance in 
clinical trials
In this section we describe five examples of informative
noncompliance, using databases from published end-
point trials. Although all the studies involve one of two
drugs (enalapril and losartan) in closely related pharma-
cological classes, and all involve patients with or at high
risk for cardiovascular disease, they cover a wide range of
situations. The specific patient populations differ in all
five trials, and the trials include various control groups
and endpoints. In three of the trials, the hazard rate is
roughly constant over time, in one trial it is clearly increas-
ing and in another it is clearly decreasing.
In all examples, we present data for the pooled treatment
groups. We have examined the results within treatment
groups and have found them to be generally consistent
with the overall results from that study. In addition, we
have examined the sensitivity of the results to the choice
of the 7-day window for determining the start of noncom-
pliance, and have found little impact.
Below is a brief description of the studies. Their results
with respect to informative noncompliance are summa-
rized in Table 2 and are illustrated in Figures 1,2,3,4,5.
• The SOLVD Treatment Trial [17] randomized 2,569
patients with left ventricular dysfunction and overt heart
failure to treatment with enalapril, an angiotensin con-
verting-enzyme inhibitor, or to placebo (Figure 1).
• The SOLVD Prevention Trial [18] randomized 4,228
patients with left ventricular dysfunction but without
symptoms of overt heart failure to treatment with enal-
april or to placebo (Figure 2).
• The RENAAL Trial [19] randomized 1,513 patients with
type 2 diabetes mellitus and nephropathy to treatment
with losartan, an angiotensin II antagonist, or to placebo
(Figure 3).
• The LIFE Trial [20] randomized 9,193 patients with
hypertension and left ventricular hypertrophy to treat-
ment with losartan or to atenolol, a beta-blocker (Figure
4).
Table 2: Results from Five Published Clinical Trials
Trial Acronym Experimental 
Treatment
Control 
Treatment
Patient 
Population
Endpoint Sample 
Size
Endpoint 
Number 
and Rate
Disconti
nuation 
Number
and Rate
Hazard Ratio 
Associated with 
Non-compliance
p-value
SOLVD-T Enalapril Placebo Left 
Ventricular 
Dysfunction 
with Overt 
Heart Failure
Total Mortality 2,569 961 
(37.4%)
839 
(32.7%)
2.7 < 0.0001
SOLVD-P Enalapril Placebo Left 
Ventricular 
Dysfunction 
without 
Overt Heart 
Failure
Total Mortality 4,228 638 
(15.1%)
987 
(23.3%)
3.2 < 0.0001
RENAAL Losartan Placebo Type 2 
Diabetes with 
Nephropathy
Doubling of 
Serum 
Creatinine, 
End-Stage 
Renal Disease 
or Death
1,513 686 
(45.3%)
469 
(31.0%)
2.6 < 0.0001
LIFE Losartan Atenolol Hypertension 
and Left 
Ventricular 
Hypertrophy
Myocardial 
Infarction, 
Stroke or 
Cardiovascular 
Death
9,193 1096 
(11.9%)
2,273 
(24.7%)
2.6 < 0.0001
OPTIMAAL Losartan Captopril High-Risk 
Acute 
Myocardial 
Infarction
Total Mortality 5,477 946 
(17.3%)
1,156 
(21.1%)
5.0 < 0.0001Current Controlled Trials in Cardiovascular Medicine 2004, 5:5 http://cvm.controlled-trials.com/content/5/1/5
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• The OPTIMAAL Trial [21] randomized 5,477 patients
with a high-risk of acute myocardial infarction to treat-
ment with losartan or to captopril, an angiotensin con-
verting-enzyme inhibitor (Figure 5).
In all of the trials presented here (Table 2), patients who
discontinued from study drug were at higher risk of expe-
riencing a study endpoint than patients remaining on
study drug. The hazard ratio ranged from 2.6 to 5.0. While
these examples do not prove that the phenomenon of
informative noncompliance exists universally, it is impor-
tant to note that these trials were not specifically chosen
to illustrate the point, but rather are representative of real
clinical trials in our experience.
Kaplan-Meier Estimates Stratified by Time-Varying Noncom- pliance in the SOLVD Treatment Trial Figure 1
Kaplan-Meier Estimates Stratified by Time-Varying Noncom-
pliance in the SOLVD Treatment Trial
Kaplan-Meier Estimates Stratified by Time-Varying Noncom- pliance in the SOLVD Prevention Trial Figure 2
Kaplan-Meier Estimates Stratified by Time-Varying Noncom-
pliance in the SOLVD Prevention Trial
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Kaplan-Meier Estimates Stratified by Time-Varying Noncom- pliance in RENAAL Figure 3
Kaplan-Meier Estimates Stratified by Time-Varying Noncom-
pliance in RENAAL
Kaplan-Meier Estimates Stratified by Time-Varying Noncom- pliance in LIFE Figure 4
Kaplan-Meier Estimates Stratified by Time-Varying Noncom-
pliance in LIFE
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Impact of informative noncompliance on sample 
size
Clearly, when patients are noncompliant with study med-
ications, the ability to detect differences between
treatment groups will be diminished. This is the reason
that existing sample size methods account for the
expected rate of noncompliance. However, it is not the
rate of noncompliance per se that is important, but rather
the proportion of endpoints that occur in noncompliant
patients. Existing sample size methods, which assume
noninformative noncompliance, can greatly underesti-
mate this proportion, and therefore may greatly underes-
timate the required sample size.
As an example, consider this relatively simple situation,
which is illustrated in Figure 6. Patients are randomized
simultaneously, and over the course of the study, the end-
point rates for the compliant patients are 10% and 8% in
the control and experimental treatment groups, respec-
tively. The discontinuation rates are 20% in each treat-
ment group. For simplicity, assume that all
noncompliance occurs immediately at the start of the trial
and that endpoint rates in noncompliant patients
correspond to those of compliant patients in the opposite
treatment group. The impact of noncompliance is to
reduce the difference between groups with respect to the
effective endpoint rates (i.e., the rates that are estimated
using an ITT analysis) relative to the difference with
respect to the ideal endpoint rates (i.e., when patients are
fully compliant).
Take first the case of noninformative noncompliance. In
the control group, the 80% of patients who are compliant
have an endpoint rate of 10% and the 20% of patients
who are noncompliant have an endpoint rate of 8%, for
an overall effective endpoint rate of 9.6%. Similarly, in the
experimental group the effective endpoint rate is 8.4%.
Since the difference between 9.6% and 8.4% is smaller
than the difference between 10% and 8%, sample size
must be increased to account for noncompliance.
Now take the case of informative noncompliance. Non-
compliance identifies a sicker subset of patients. For
example, if they remained on the control therapy,
noncompliant patients in the control group might be
expected to have an endpoint rate of, say, 20%, and com-
pliant patients might be expected to have an endpoint rate
of, say, 7.5%. Note that this would result in an overall
endpoint rate of 10%, as in the case of noninformative
noncompliance. However, since the noncompliant
patients become treated, their endpoint rate becomes
16%, and the effective endpoint rate in the control group
is 9.2% (7.5% among the 80% of patients who are com-
pliant and 16% among the 20% of patients who are
noncompliant). By a similar argument, noncompliant
patients in the treatment group have an endpoint rate of
20% (16% had they remained treated) and compliant
patients have an endpoint rate of 6%, for an effective end-
point rate of 8.8% (6% among the 80% of patients who
are compliant and 20% among the 20% of patients who
are noncompliant). Therefore, informative noncompli-
ance has further decreased the difference between the
effective endpoint rates, which exacerbates the effect of
noncompliance on power and sample size.
Now consider the impact of noncompliance on sample
size. As above, assume that the endpoint rates in the two
treatment groups are 8% and 10%, and ignore other fac-
tors that could influence sample size, such as staggered
entry and treatment lag. Using the Lakatos method [11],
the total sample size required for 90% power at a two-
sided 5% significance level is 8,600 patients if we
disregard noncompliance, and 11,890 patients if we
account for noncompliance rates of 15% in each treat-
ment group. If we further assume that noncompliance is
informative and that the hazard ratio associated with non-
compliance is 2, then using a modified version of the
Lakatos method [22], the required sample size is 16,330
patients, and the power associated with a sample size of
11,890 patients is 79.0%. Based on this example, inform-
ative noncompliance is clearly an important factor in the
calculation of sample size.
Conclusions
Noncompliance is present to some extent in virtually all
clinical trials, but is typically a more serious concern in
Kaplan-Meier Estimates Stratified by Time-Varying Noncom- pliance in OPTIMAAL Figure 5
Kaplan-Meier Estimates Stratified by Time-Varying Noncom-
pliance in OPTIMAAL
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long-term endpoint trials of chronic therapies. While it is
common to account for noncompliance in the calculation
of sample size for these trials, existing methods assume
that noncompliance is noninformative. In this paper we
have shown that the assumption of noninformative
noncompliance is often invalid, and that this can lead to
incorrect sample size.
The presence of informative noncompliance can have two
fundamentally different interpretations. First, it is possi-
ble that discontinuation from study drug is harmful to the
patient, thereby causing the endpoint rate to increase. We
believe that this interpretation is unlikely to be true in
most cases. Of note, in the SOLVD and RENAAL trials, the
risk of an endpoint was elevated to roughly the same
degree in patients who discontinued from placebo as in
patients who discontinued from active drug. It is more
likely that noncompliance tends to occur in sicker patients
who are at higher endpoint risk, regardless of discontinu-
ation. For example, patients might experience severe
symptoms of their condition, causing them to discontinue
from study therapy and seek more effective therapies. This
is supported by the observation that patients who discon-
tinue often have high-risk characteristics at baseline.
Regardless of the cause, however, the result of informative
noncompliance is that an increased fraction of the study
endpoints occur in patients who are no longer taking
study drug. This, in turn, affects power.
Noncompliance can take many forms. Patients may take
incorrect doses, miss doses, temporarily interrupt therapy,
or permanently discontinue it. Temporary interruptions
and permanent discontinuations can be initiated by the
patient or the physician. Incorrect and missed doses are
notoriously difficult to assess. Attempts to measure them
by such methods as pill counts are easily thwarted by
patients who want to appear to be compliant. Regardless
of its form, noncompliance can have an important impact
on power. In this paper, we have focused on permanent
discontinuation, the form that is easiest to measure.
While informative noncompliance typically has not been
considered with respect to sample size calculation, it has
always been a consideration at the time of analysis.
Difference between Effective Endpoint Rates in the Treatment (Left) and Control (Right) Groups Figure 6
Difference between Effective Endpoint Rates in the Treatment (Left) and Control (Right) Groups. A: Full Compliance. B: Non-
informative Noncompliance. C: Informative Noncompliance.
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Although various analysis models exist, ITT has become
the standard analysis approach for endpoint trials. If non-
compliance could be assumed to be noninformative, we
could obtain an unbiased estimate of the parameter of
interest, the effect of the study treatment when patients
are compliant, by censoring patients at the time of
discontinuation (i.e., an "on treatment" analysis). In the
presence of informative noncompliance, however, the
"on treatment" analysis can be biased in either direction,
depending on the levels of noncompliance and the rela-
tive degrees of informativeness in the two treatment
groups. Although the ITT analysis will also give a biased
estimate of the treatment effect, this approach is preferred,
since noncompliance tends to diminish the difference
between treatment groups, resulting in a conservative
bias.
While noncompliance is an issue that can impact power in
all types of clinical trials, informative noncompliance is of
particular concern in endpoint trials, since information
on the treatment effect comes primarily from the subset of
patients experiencing endpoints. Thus, a particularly high
noncompliance rate among patients who are most likely
to experience an endpoint will have a considerably large
impact on sample size and power. Conversely, in trials
where the efficacy measure is a normally distributed vari-
able, on the other hand, all patients contribute informa-
tion and it makes little difference whether noncompliance
occurs in patients with typical values or extreme values of
the response variable.
As stated, the assumption of noninformative noncompli-
ance implies that if they were to be treated identically,
compliant and noncompliant patients would be at identi-
cal risk of experiencing a study endpoint. Compliant and
noncompliant patients however are not treated identi-
cally. By definition, compliant patients remain on study
therapy, while noncompliant patients do not. Therefore,
the hazard ratio associated with noncompliance actually
measures a combination of two factors: the inherent dif-
ference in risk between compliant and noncompliant
patients (the factor of interest) and the impact of differen-
tial treatment between these patients. We do not believe
that the latter factor had much practical impact in the
examples presented here, the reasons being that 1) the
magnitudes of the hazard ratios (2.6 to 5.0) far exceed the
typical risk reductions due to therapies in these patients
(on the order of 15–20%) and 2) when we examined the
hazard ratios within each treatment group separately, the
results were typically similar to those of the pooled
groups.
In conclusion, informative noncompliance is a common
phenomenon in endpoint trials that can have a dramatic
impact on sample size and power. Appropriately account-
ing for informative noncompliance should become an
important component of sample size planning.
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